Home ›› 21 Jan 2022 ›› Stock
IBN SINA Pharmaceutical Industry has registered a 28 per cent growth in its profits for the first half (July-December) in the financial year 2021-22, thanks to increased sales amid the Covid-19 pandemic.
The listed drug maker reported earnings per share (EPS) of Tk 10.49 for the July-December period of FY22, up by 28 per cent from Tk 8.19 in the same period of previous year, according to the half yearly unaudited financial statement.
The board of directors of the company in its 293rd meeting on Thursday approved the half yearly unaudited financial statements.
However, the company’s net operating cash flow declined to Tk 9.74 during the period from Tk 10.48 of the same period in the previous year.
It reported an EPS of Tk 5.97 in the second quarter of FY22, up by 21 per cent from Tk 4.95 of previous year’s same quarter.
On Thursday, IBN SINA share inceased slightly to Tk 290 at the Dhaka bourse. The price moved between Tk 226.10 and Tk 306.90 throughout the last one year.
The pharma company distributed 47 per cent cash dividend to the shareholders for the financial year ended on June 30, 2021.
The company incorporated in 1983 and listed in capital market 1989. It exports medicine to 10 countries and increasing the foreign currency earning. It has more than 450 types of medicine products.
